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uPAR in acute 
pyelonephritis
Th e urokinase plasminogen activator 
receptor (uPAR) is a glycosyl 
phosphoinositide-linked protein that 
interacts with other G protein-coupled 
receptors to induce a variety of cellular 
functions, including migration. It is 
expressed in infl ammatory cells but also 
on renal tubular epithelial cells. During 
acute infections with Escherichia coli, 
uPAR levels in the blood and urine 
increase. As they report in this issue, 
Roelofs et al. studied the role of this 
receptor in acute pyelonephritis. 
Th ey infected mice whose uPAR was 
deleted by homologous recombination 
with uropathogenic E. coli and 
studied the infl ux of neutrophils 
into renal parenchyma. Th ey found 
that the mutant mice had a higher 
amount of bacteria and higher levels 
of infl ammatory cytokines such as 
interleukin-1β, interleukin-6, and 
tumor necrosis factor-α. However, 
the number of infi ltrating neutrophils 
was identical to that found in wild-
type mice when given the same dose 
of infection. In these studies, the 
mutant neutrophils were unable to 
eliminate bacteria as effi  ciently as 
those with normal uPAR. Studies of 
isolated neutrophils from wild-type 
and mutant mice showed that the 
mutant neutrophils were less effi  cient 
at phagocytosis of presented E. coli, 
although their ability to generate 
reactive oxygen species was similar to 
that of wild-type cells. Th ese studies 
demonstrate that uPAR is clearly 
involved in the phagocytosis of bacteria 
in the urinary tract during acute 
pyelonephritis. See page 1942.
Where do 
nephrologists publish 
their results?
Th e reading habits of physicians and 
nephrologists vary. Hence, where 
important articles get published is 
important in guiding nephrologists. 
Garg et al. studied this using a 
published database focusing on reviews 
that pertain to clinical practice. An 
analysis of these data over the last 
40 years showed that almost half of the 
studies were published in the same 20 
journals, which included renal specialty 
journals such as Kidney International, 
Transplantation Proceedings, and so 
on. However, there were also ten non-
renal journals on this list, including the 
Lancet and the New England Journal 
of Medicine. Th e remaining 50% of 
papers were published in more than 
400 other journals. Th e publication 
of important reviews that aff ect renal 
practice in non-renal journals is not 
surprising by itself. One would have 
liked to see whether authors sent the 
papers they thought would have the 
largest impact on renal practice to renal 
specialty journals or to general-interest 
ones. Th e more ‘important’ a study is 
considered to be, the more widely it 
ought to be disseminated; hence one 
would think that authors would send 
such papers fi rst to journals that all 
physicians, not just nephrologists, read. 
Almost half of reviews were published 
among 400 journals rather than in 
renal-specifi c ones. Th e real question is 
whether scanning these reviews made 
a diff erence to the busy clinician. To 
determine that, a completely diff erent 
study is needed. See page 1995.
Exclusion of CKD from 
trials of coronary 
artery disease
Another paper in this issue examines 
several published studies on the 
outcome of cardiovascular events in 
a large number of clinical trials that 
dealt with therapies for coronary artery 
disease. Although all of these studies 
were randomized clinical trials, there 
was a surprising lack of patients with 
chronic kidney disease. It appeared that 
such patients were specifi cally excluded 
in more than 80% of these trials! It seems 
that the researchers did not exclude 
serious illnesses from their analysis, as 
subjects with diabetes, hypertension, 
or a history of smoking were excluded 
from the trials less than 4% of the 
time. Th e exclusion of patients with 
chronic kidney disease in clinical trials 
of coronary artery disease represents a 
disservice, since coronary artery disease 
is so common in patients with chronic 
kidney disease. We urgently need, as 
a community, to rectify this issue. See 
page 2021.
